NCT03283228

Brief Summary

  1. 1.Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
  2. 2.Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2017

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2017

Completed
18 days until next milestone

First Posted

Study publicly available on registry

September 14, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

December 1, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2019

Completed
Last Updated

September 14, 2017

Status Verified

September 1, 2017

Enrollment Period

1 year

First QC Date

August 27, 2017

Last Update Submit

September 12, 2017

Conditions

Adult Acute Myeloid Leukemia

Outcome Measures

Primary Outcomes (1)

  • CD11b and CD56 marker

    Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

    24 month

Study Arms (2)

CD11b and CD56 markers

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Diagnostic Test: Cd11b and Cd56 markers

Haematological parameters in cases of adult AML

Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML

Diagnostic Test: Cd11b and Cd56 markers

Interventions

Cd11b and Cd56 markersDIAGNOSTIC_TEST

The expression of CD11b and CD56 in newly diadnosed cases of AML

Also known as: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
CD11b and CD56 markersHaematological parameters in cases of adult AML

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Anew diagnosis cases of adult AML

You may qualify if:

  • Anew diagnosis cases of adult AML

You may not qualify if:

  • Pediatric AML .
  • follow up cases of adult AML

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Central Study Contacts

Shaaban Helal, PHD

CONTACT

01005688567Elhelal2007@gmail.com

Eman Salah Eldin, lecture

CONTACT

01028030966Emansalah.eldin@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

August 27, 2017

First Posted

September 14, 2017

Study Start

December 1, 2017

Primary Completion

December 1, 2018

Study Completion

October 1, 2019

Last Updated

September 14, 2017

Record last verified: 2017-09